Generic Drugs – SRK Analytics

Cipla Secures US FDA Approval for Generic Advair Diskus Across All Strengths

Indian pharmaceutical major Cipla Limited has secured final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for generic Advair Diskus. The regulatory clearance…

Prasenjit Bhowmik July 28, 2026

Business Insights

Aurobindo Pharma Secures Merck Licensing Deal to Expand Generic HIV Drug Access Across 129 Nations

Indian pharmaceutical major Aurobindo Pharma Limited has signed a strategic voluntary licensing agreement with US-based Merck & Co. to manufacture and supply generic versions of a key HIV drug across…

Prasenjit Bhowmik July 25, 2026

Market

Trump’s Proposed Generic Medicine Tariffs Trigger 4% Slump in Indian Pharma Stocks

On July 24, major Indian pharmaceutical stocks plummeted by as much as 4% after U.S. President Donald Trump announced a proposed phased tariff plan on imported generic medicines, sparking immediate…

Prasenjit Bhowmik July 24, 2026

Business Insights

Indian Pharma Sector Pivots as US Evaluates Steep Tariffs on Generic Drug Imports

Discover how Indian drugmakers are adapting to potential US tariffs on generic imports while maintaining their global lead in affordable healthcare.

Prasenjit Bhowmik July 24, 2026

Business Insights

Granules India Warns US Tariff Plans Cannot Easily Overcome High Domestic Drug Manufacturing Costs

Indian pharmaceutical major Granules India announced from its Hyderabad headquarters that relocating large-scale generic drug manufacturing to the United States remains highly impractical due to steep domestic operating costs, despite…

Prasenjit Bhowmik July 22, 2026

Business Insights

Jubilant Pharmova Subsidiary Secures Tentative USFDA Nod for Pantoprazole Oral Suspension

Jubilant Generics' tentative USFDA approval for Pantoprazole Oral Suspension marks a key milestone, paving the way for future market entry in 2026.

Prasenjit Bhowmik June 28, 2026